
Combating viruses is often a frustrating business. Find a way to destroy them --- and before you know it, they’ve found a way to defend themselves and neutralize the anti-viral treatment.
How, exactly, do the viruses do it? In an article published as the cover story in a recent issue of the journal Proteins, a Hebrew University of Jerusalem researcher, Prof. Isaiah (Shy) T. Arkin, has revealed just how influenza-causing viruses adapt to nullify the effectiveness of the anti-viral drug symmetrel (generic name). The revelation can have significant consequences in leading drug researchers to develop new and more effective means to block influenza and other viruses in the future.
Influenza, Prof. Arkin emphasizes, is a major killer, even though many people tend to shrug it off as an unpleasant seasonal nuisance. In the U.S. it is the leading cause of death from infectious diseases, claiming about 40,000 lives annually, mostly among the elderly.
In his research, Arkin, of the Department of Biological Chemistry at the Hebrew University’s Silberman Institute of Life Sciences, has demonstrated how flu viruses counteract the symmetrel drug. Assisting him in his work were graduate students Peleg Astrahan and Itamar Kass, as well as Dr. Matt Cooper from Cambridge University in Britain.
Administered at an early stage at the onset of flu symptoms, symmetrel is intended to destroy the virus by binding to and blocking a proton-conducting channel which the virus needs in order to continue functioning and multiplying.
Rather than conceding defeat, however, the virus takes its own counteractions: either by narrowing its channel to the extent that the blocking element in the drug is unable to bind and create a seal, or by widening its channel so that the blocker can get in, but can’t totally seal the channel. Arkin notes that the latter action is the more surprising and unexpected one.
While counteraction of the virus to the drug has been previously noted, this is the first time that the activity that lies behind this phenomenon has been demonstrated, said Arkin. This is because researchers had previously only concentrated on examining the binding action of the blocker to the viruses, but not the process taking place in the viruses’channel. Thus, there was only a limited picture of what was actually happening.
This new information on the mutating abilities of the influenza virus will have to be taken into consideration in further anti-viral research, said Arkin.
Jerry Barach | Source: alphagalileo
Further information: www.huji.ac.il
More articles from Health and Medicine:
Polyphenols and polyunsaturated fatty acids boost the birth of new neurons
25.11.2009 | Universitat Autonoma de Barcelona
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
24.11.2009 | Johns Hopkins Medical Institutions
First black holes may have incubated in giant, starlike cocoons
25.11.2009 | Physics and Astronomy
KfW issues its first ever 7 year Euro-Benchmark
25.11.2009 | Business and Finance
Intelligence inside metal components
25.11.2009 | Information Technology
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News